The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading; there are no other matters the omission of which would make any statement in this announcement misleading; and all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(incorporated in the Cayman Islands with limited liability)

RESULTS OF PLACING OF 20,000,000 NEW SHARES

Reference is made to the announcement of the Company dated 13 September, 2002.

DBS Asia has successfully placed a total of 20,000,000 new Shares on behalf of the Company to the Placees which are Independent Third Parties.

Completion of the Placing is conditional upon the GEM Listing Committee granting the listing of, and permission to deal in, the Placing Shares. Completion of the Placing is expected to take place on the second Business Day following the fulfillment of the condition of the Placing, which is expected to be on or before 12 October, 2002.

Reference is made to the announcement of Sino Biopharmaceutical Limited (the "Company") dated 13 September, 2002 (the "Announcement"). Unless otherwise stated, capitalised terms used in this announcement shall have the same meanings as defined in the Announcement.

The board of Directors (the "Board") is pleased to announce that DBS Asia has successfully placed a total of 20,000,000 new Shares on behalf of the Company to 11 independent placees (the "Placees") on 17 September, 2002.

The Placees are Independent Third Parties, and none of the Placees fall under any of the categories set forth in Note 1 to Rule 10.12(4) of the GEM Listing Rules.

The Placing Shares represent approximately 6.67% of the existing issued share capital of the Company and approximately 6.25% of the issued share capital of the Company as enlarged by the Placing.

The shareholding interests in the Company held by the 10 largest Placees immediately following the completion of the Placing are as follows:-

Top ten largest Placees	Percentage of the Placing Shares	Percentage of the issued share capital of the Company immediately after completion of the Placing
1	19.00%	1.19%
2	19.00%	1.19%
3	13.00%	0.81%
4	12.50%	0.78%
5	12.25%	0.77%
6	11.00%	0.69%
7	10.00%	0.63%
8	2.50%	0.16%
9	0.25%	0.02%
10	0.25%	0.02%
Total	99.75%	6.23%

Completion of the Placing is conditional upon the GEM Listing Committee granting the listing of, and permission to deal in, the Placing Shares. Completion of the Placing is expected to take place on the second Business Day following the fulfillment of the condition of the Placing, which is expected to be on or before 12 October, 2002.

By order of the Board Sino Biopharmaceutical Limited Tse Ping Chairman

Hong Kong, 3 October, 2002

This announcement will remain on the "Latest Company Announcements" page on the GEM website at www.hkgem.com for at least 7 days from the day of its posting and on the Company's website at www.sinobiopharm.com.